
Head & Neck Surgery Resident @UHcleENT | Product of @cwrusom and @caseweatherhead | Passionate about Cleveland Sports
Cleveland, OH
Joined August 2018
- Tweets246
- Following709
- Followers584
- Likes8.2K
So proud of my Dad @VisageFaceMD for following his dream and going back to school to get his MBA @caseweatherhead. Finally gonna get to give back and teach him a thing or two (hopefully!)
Humzah A. Quereshy, MD, MBA retweeted
We are HIRING 2 Research Fellows for 2023-2024, see info about the opportunity below!
Dr Dorth is a leader in Rad Onc for H&N Cancer.
So grateful we get to spend parts of our 1 month elective with her during our intern year at @UHcleENT
Replying to @DrSpratticus
Dr. Jen Dorth giving a masterclass on head and neck cancers.
Discussed the numerous neg IO trials in this space unfortunately.
@TedTeknosMD @RadoncUh @ClevelandClinic @caseccc @DrJohnSuh
Humzah A. Quereshy, MD, MBA retweeted
In this study from @UofT_OHNS, patients with #HeadAndNeckCancer earning <$30,000 per year were twice as likely than patients with higher income to experience a disease recurrence. ja.ma/3XraTNe @chrisnoelmd @DrJohndeAlmeida @ihpmeuoft
Humzah A. Quereshy, MD, MBA retweeted
As a med student, it’s hard to feel like I’m making an impact on patient care… But last week a patient couldn’t get a life saving drug we prescribed because the copay was $1700/mo and I showed the team @costplusdrugs where the drug was $112/mo, which he could afford!
Humzah A. Quereshy, MD, MBA retweeted
Casually mentioned to my chief that I was a bit upset for missing 3 prayers today and needed to work on being more efficient. She stopped what she was doing, wrote down my prayer times and asked “how can we best accommodate your prayer times?” 🥺made my whole week #MedTwitter
Humzah A. Quereshy, MD, MBA retweeted
"Although many factors ultimately determine program expansion or development of new training programs, this study provides substantiated population data describing where expansion could be prioritized." #OtolaryngologyWorkforce #MedEd #ENTSurgery doi.org/10.1002/lary.30361
Humzah A. Quereshy, MD, MBA retweeted
We are elated that @UHhospitals Ear, Nose, and Throat specialty care was ranked No. 17 nationally by
@USNewsHealth. Additionally UH ENT ranked BEST in Ohio for Ear, Nose, and Throat! health.usnews.com/best-hospi…
Humzah A. Quereshy, MD, MBA retweeted
🎙"We need to do more research to better fine-tune adjuvant treatment paradigms for patients with microscopic and macroscopic extranodal extension," says Brooke Quinton of @CWRUSOM
Read more here: bit.ly/3vF6URn
#AHNS2022 #oncology @BrookeQuinton @AHNSinfo
Humzah A. Quereshy, MD, MBA retweeted
Physicians with Urdu speaking patients: This was a simple enough read on blood clots.
Please also note that most Urdu speaking patients are Muslim and you should have a conversation about heparin and other pork derived medications. Below are some consideration for that convo 1/n
Replying to @SharinStone @HopkinsMedicine @LauzeeTweet @CMAJ_Open @pbatesmurphy @StopTheClot @PCORI @JHM_Armstrong
Our official @HopkinsMedicine #BloodClot #PatientEducation in now avialable #Urdu hopkinsmedicine.org/armstron…
Humzah A. Quereshy, MD, MBA retweeted
As a senior in hs, Jordan Poole came off the bench.
He didn’t start a game his 1st year at Michigan.
He spent last year in the G-League.
He’s now averaging 30ppg in the NBA Playoffs.
Just because it’s not your turn right now doesn’t mean your time isn’t coming. Keep working.
My close friend and now colleague @NateFarrokhian doing great work investigating a predictive model on occult nodal disease in Oral SCC. @KU_ENT got a good one!
TWEETORIAL on our @JAMANetworkOpen article: Development and Validation of Machine Learning Models for Predicting Occult Nodal Metastasis in Early-Stage OCSCC. @drandresbur @KU_ENT @VanderbiltENT @IowaOto @MassEyeAndEar @MizzouENT @ent_umn
doi.org/10.1001/jamanetworko…
1/
Humzah A. Quereshy, MD, MBA retweeted
Cavs had a helluva a year and Cleveland sports is gonna be scary next year…
Humzah A. Quereshy, MD, MBA retweeted
ift.tt/FZN1kGR Medicare reimbursement trends from 2000 to 2020 in head and neck surgical oncology
























